The IMPAACT Network is a cooperative group of institutions, investigators, and other collaborators focused on evaluating potential therapies for HIV infection and its related symptoms in infants, children, adolescents, and pregnant women, including clinical trials of HIV/AIDS interventions for and prevention of mother-to-child transmission.

The IMPAACT Network resulted from the merger of two predecessor networks: the Pediatric AIDS Clinical Trials Group and the perinatal scientific working group of the HIV Prevention Trials Network. It is co-funded by the NICHD Maternaland Pediatric Infectious Disease Branch (MPIDB)(formerly the Pediatric, Adolescent, and Maternal AIDS Branch) and the National Institute of Allergy and Infectious Diseases, and receives funding from other NIH Institutes and Offices, including the National Institute of Mental Health.

As an international project, the IMPAACT Network includes both a domestic research agenda and an international research agenda. The domestic research agenda includes a focus on evaluating the pharmacokinetics, safety, optimal dosing, and long-term complications of new antiretroviral (ARV) therapies for HIV/AIDS in pediatric and adolescent populations, among other topics and activities. The international research agenda includes a focus on the prevention of mother-to-child transmission of HIV and reduction of maternal and infant morbidity and mortality from HIV/AIDS through studies such as Promoting Maternal and Infant Survival Everywhere (PROMISE).

The IMPAACT Network collaborates with the NICHD Domestic and International Pediatric/Maternal HIV Clinical Studies Network, the Adolescent Medicine Trials Network for HIV/AIDS Interventions, and with other NICHD-, NIH-, and organization-led HIV/AIDS research networks and projects.

The IMPAACT Network conducts clinical trials of HIV/AIDS therapy and prevention in maternal, pediatric, and adolescent patients.